BioCentury | Apr 14, 2017
Emerging Company Profile

Tolerating DHODH

...8 Funds raised: €21.7 million ($23.4 million) Investors: LSP, LifeCare Partners, Bayern Kapital, High-Tech Gründerfonds, IBG Risikokapitalfonds...
BioCentury | Feb 3, 2017
Financial News

Immunic completes venture financing

...a series A round, bringing the total raised to €21.7 million ($24.2 million). New investor IBG Risikokapitalfonds...
BioCentury | Nov 9, 2009
Financial News

Probiodrug completes venture financing

Probiodrug AG , Halle/Saale, Germany Business: Neurology, Endocrine, Autoimmune Date completed: 11/2/09 Type: Venture financing Raised: €36 million ($53.2 million) Investors: BB Biotech Ventures; Edmond de Rothschild Investment Partners; LSP-Life Sciences Partners; Biogen Idec New Ventures;...
Items per page:
1 - 3 of 3
BioCentury | Apr 14, 2017
Emerging Company Profile

Tolerating DHODH

...8 Funds raised: €21.7 million ($23.4 million) Investors: LSP, LifeCare Partners, Bayern Kapital, High-Tech Gründerfonds, IBG Risikokapitalfonds...
BioCentury | Feb 3, 2017
Financial News

Immunic completes venture financing

...a series A round, bringing the total raised to €21.7 million ($24.2 million). New investor IBG Risikokapitalfonds...
BioCentury | Nov 9, 2009
Financial News

Probiodrug completes venture financing

Probiodrug AG , Halle/Saale, Germany Business: Neurology, Endocrine, Autoimmune Date completed: 11/2/09 Type: Venture financing Raised: €36 million ($53.2 million) Investors: BB Biotech Ventures; Edmond de Rothschild Investment Partners; LSP-Life Sciences Partners; Biogen Idec New Ventures;...
Items per page:
1 - 3 of 3